Implementing the EffTox dose-finding design in the Matchpoint trial
Author:
Funder
Bloodwise
Publisher
Springer Science and Business Media LLC
Subject
Health Informatics,Epidemiology
Link
http://link.springer.com/content/pdf/10.1186/s12874-017-0381-x.pdf
Reference35 articles.
1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med. 2006; 355(23):2408–17.
2. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia : 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014; 123(4):494–501. doi: 10.1182/blood-2013-06-511592 .
3. Larson R, Hochhaus A, Hughes T, Clark R, Etienne G, Kim DW, Flinn I, Kurokawa M, Moiraghi B, Yu R, Blakesley R, Gallagher N, Saglio G, Kantarjian H. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase : ENESTnd 3-year follow-up This article has been corrected since Advance Online Publication and a corrigendum is also printed. Leukemia. 2012; 26:2197–203. doi: 10.1038/leu.2012.134 .
4. Hehlmann R. How I treat CML blast crisis How I treat How I treat CML blast crisis. Blood. 2012; 120(4):737–48. doi: 10.1182/blood-2012-03-380147 .
5. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344(14):1038–42.
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Accelerated-phase CML: de novo and transformed;Hematology;2023-12-08
2. Early phase clinical trials in oncology: Realising the potential of seamless designs;European Journal of Cancer;2023-08
3. Adaptive Cohort Size Determination Method for Bayesian Optimal Interval Phase I/II Design to Shorten Clinical Trial Duration;JCO Precision Oncology;2023-07
4. A Multi-Armed Bayesian Ordinal Outcome Utility-Based Sequential Trial with a Pairwise Null Clustering Prior;Bayesian Analysis;2023-06-01
5. Model-Based Designs for Identification of Optimal Biological Dose;Bayesian Adaptive Design for Immunotherapy and Targeted Therapy;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3